Immupharma PLC Holding(s) in Company (7093V)

TIDMIMM

RNS Number : 7093V

Immupharma PLC

30 October 2014

 
  FOR IMMEDIATE RELEASE    30 OCTOBER 2014

NOTIFICATION OF ODEY'S MAJOR INTEREST IN SHARES

Following the Recent Successful GBP3.4m Fund Raising

ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, is pleased to confirm that its long standing shareholder Odey Asset Management ("Odey") has increased its shareholding in ImmuPharma Ordinary Shares to 3,433,319 representing a 3.87% shareholding in the Company.

This follows last week's announcement from ImmuPharma that Odey with Aviva plc were lead investors in a GBP3.4 million fund raising to support the pivotal phase III progress of Lupuzor(TM) , the Company's lead candidate for the treatment of lupus, a potentially life threatening auto-immune disease.

Commenting on this announcement, Richard Warr, Chairman said: "Odey has been a key investor in ImmuPharma since the Company's inception. We are therefore delighted to have received further support from this major shareholder for our plans to take Lupuzor(TM) through its pivotal Phase III development."

For further information please see the Group's web site, www.immupharma.com, or contact:

 
                                          + 44 (0) 20 7152 
  ImmuPharma plc                                      4080 
  Dimitri Dimitriou, Chief 
   Executive Officer 
  Dr Robert Zimmer, President 
   and Chief Scientific Officer 
  Richard Warr, Chairman 
  Tracy Weimar, Vice President, 
   Operations and Finance 
  Lisa Baderoon, Head of Investor 
   Relations                          + 44 (0) 7721 413496 
 
  Panmure, Gordon & Co., NOMAD 
   & Broker                           +44 (0) 20 7886 2500 
  Hugh Morgan, Fred Walsh, 
   Duncan Monteith

This information is provided by RNS

The company news service from the London Stock Exchange

END

HOLFBLFXZBFBFBK

Immupharma (LSE:IMM)
Historical Stock Chart
From Jun 2024 to Jul 2024